Search Results

Featured Stories

Toggle

Showing 10 of 304 results

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability...

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

January 12, 2021 /3BL Media/  - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced long-term environmental sustainability commitments and targets to provide direction and drive...

Teva Reports Third Quarter 2020 Financial Results

Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billio...

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Teva’s Digital Inhaler Portfolio Now Powered by AWS TEL AVIV, Israel & PARSIPPANY, N.J. & SAN ANTONIO--(BUSINESS WIRE)-- Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd....

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY

Analysis assessed migraine days at the beginning and end of quarterly and monthly dosing intervals TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) toda...

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disopro

  TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the availability of t...

Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol

- The first and only family of digital, breath-actuated inhalers with built-in sensors that track inhaler events and measure inspiratory flow - Digihaler ® app provides patients the ability to view...

First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Publish

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly AJOVY® (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Eval

Additional data to be presented examining the safety and tolerability of AUSTEDO during periods of titration and maintenance

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psyc

JERUSALEM & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO® (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.